PIONYR IMMUNOTHERAPEUTICS
Gilead nears deal to buy Immunomedics for more than $20 billion: ReportA deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer ca...
- Load More